THE PHARMACY TO THE WORLD

The future roadmap for the Indian pharmaceutical sector will hinge on R&D, innovation, sustainability and skills development, transitioning from Make in India’ to Discover and Make in India for the World’

- Satish Reddy

Our founder, the late Dr Anji Reddy, chose to call his memoirs An Unfinished Agenda-the unfinished part being the discovery, development and commercialisation of a new drug by Dr. Reddy's in his time. While our company initiated new drug discovery in 1992, the cost and risks of going beyond early-stage discovery were prohibitive to the young company.

It was Dr Anji Reddy's dream to see Indian pharma successfully discover and take a pipeline of new molecules to the market and become an original innovation-driven industry.

Global manufacturing prowess: Today, India is the largest provider of generic drugs globally. Indian pharma supplies over 50 per cent of the global demand for various vaccines, 40 per cent of the generic demand in the US and 25 per cent of all medicines in the UK. Globally, India ranks third in terms of pharmaceutical production by volume and 14th by value.

We built world-class capabilities in bulk drugs or API (Active Pharmaceutical Ingredients) in the mid-20th century, turning our attention to formulations and newer dosage forms in the 1990s, and entering new markets to break new frontiers internationally. We moved up the value chain in complexity from simple to complex molecules with higher entry barriers, cutting-edge technology platforms, devices, new chemical entities, biosimilars and biologics.

The Indian pharma industry is known as the 'pharmacy of the world' thanks to its manufacturing prowess, and stands for affordability, access, agility and quality.